| Autor: |
Shannon L. Reynolds, Sameer R. Ghate, Richard Sheer, Pranav K. Gandhi, Chad Moretz, Cheng Wang, Stephen Sander, Mary E. Costantino, Srinivas Annavarapu, George Andrews |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
Health and Quality of Life Outcomes, Vol 15, Iss 1, Pp 1-9 (2017) |
| Druh dokumentu: |
article |
| ISSN: |
1477-7525 |
| DOI: |
10.1186/s12955-017-0705-x |
| Popis: |
Abstract Background Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource utilization (HCRU) and similar total costs. This study expands on previous work by comparing HCRU and costs for patients newly diagnosed with NVAF and newly initiated on dabigatran or warfarin, and is the first study specifically in a Medicare population. Methods A retrospective matched-cohort study was conducted using data from administrative health care claims during the study period 01/01/2010–12/31/2012. Cox regression analyses were used to compare all-cause risk of first hospitalizations and emergency room (ER) visits. Medical, pharmacy, and total costs per-patient-per-month (PPPM) were compared between dabigatran and warfarin users. Results A total of 1110 patients initiated on dabigatran were propensity score-matched with corresponding patients initiated on warfarin. The mean number of hospitalizations (0.92 vs. 1.13, P = 0.012), ER visits (1.32 vs. 1.56, P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
